Kinetics of archived M184V mutation in treatment-experienced virally suppressed HIV-infected patients.
暂无分享,去创建一个
V. Calvez | R. Tubiana | C. Katlama | L. Cuzin | L. Schneider | M. Valantin | R. Palich | S. Seang | B. Abdi | E. Teyssou | A. Marcelin | C. Soulié | V. Pourcher | M. Wirden | S. Sayon
[1] C. Delaugerre,et al. Deep sequencing analysis of M184V/I mutation at the switch and at the time of virological failure of boosted protease inhibitor plus lamivudine or boosted protease inhibitor maintenance strategy (substudy of the ANRS-MOBIDIP trial). , 2021, The Journal of antimicrobial chemotherapy.
[2] J. Arribas,et al. Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study. , 2020, The Journal of antimicrobial chemotherapy.
[3] Hezhao Ji,et al. Next-Generation Sequencing for HIV Drug Resistance Testing: Laboratory, Clinical, and Implementation Considerations , 2020, Viruses.
[4] R. Siliciano,et al. Intact proviral DNA levels decline in people with HIV on antiretroviral therapy , 2019 .
[5] D. Hober,et al. Routine drug resistance testing in HIV-1 proviral DNA, using an automated next- generation sequencing assay. , 2019, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[6] K. Metzner,et al. Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART , 2019, Nature Communications.
[7] A. d’Arminio Monforte,et al. Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients , 2019, Open forum infectious diseases.
[8] V. Calvez,et al. Ultrasensitive Human Immunodeficiency Virus Type 1 Viral Load as a Marker of Treatment Choice for Simplification Strategies , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] R. Harrington,et al. HIV DNA levels and decay in a cohort of 111 long-term virally suppressed patients , 2018, AIDS.
[10] C. Delaugerre,et al. Ultra-deep sequencing improves the detection of drug resistance in cellular DNA from HIV-infected patients on ART with suppressed viraemia , 2018, The Journal of antimicrobial chemotherapy.
[11] V. Calvez,et al. Dynamics of drug resistance-associated mutations in HIV-1 DNA reverse transcriptase sequence during effective ART , 2018, The Journal of antimicrobial chemotherapy.
[12] R. Maserati,et al. Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study , 2018, Open forum infectious diseases.
[13] Philip L. Tzou,et al. Comparison of an In Vitro Diagnostic Next-Generation Sequencing Assay with Sanger Sequencing for HIV-1 Genotypic Resistance Testing , 2018, Journal of Clinical Microbiology.
[14] R. Paredes,et al. The Role of HIV‐1 Drug‐Resistant Minority Variants in Treatment Failure , 2017, The Journal of infectious diseases.
[15] M. Peeters,et al. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial. , 2017, The lancet. HIV.
[16] C. Katlama,et al. Individualized antiretroviral therapeutic approaches: less can be more , 2017, AIDS.
[17] C. Rouzioux,et al. Total HIV-1 DNA, a Marker of Viral Reservoir Dynamics with Clinical Implications , 2016, Clinical Microbiology Reviews.
[18] R. Dewar,et al. Defective HIV-1 proviruses produce novel protein-coding RNA species in HIV-infected patients on combination antiretroviral therapy , 2016, Proceedings of the National Academy of Sciences.
[19] R. Siliciano,et al. Defective proviruses rapidly accumulate during acute HIV-1 infection , 2016, Nature Medicine.
[20] C. Fagard,et al. Drug resistance and tropism as markers of the dynamics of HIV-1 DNA quasispecies in blood cells of heavily pretreated patients who achieved sustained virological suppression. , 2016, The Journal of antimicrobial chemotherapy.
[21] Trevor Bedford,et al. Persistent HIV-1 replication maintains the tissue reservoir during therapy , 2015, Nature.
[22] C. Charpentier,et al. Levels of intracellular HIV-DNA in patients with suppressive antiretroviral therapy , 2015, AIDS.
[23] Jeffrey N. Martin,et al. HIV Drug Resistance Testing by High-Multiplex “Wide” Sequencing on the MiSeq Instrument , 2015, Antimicrobial Agents and Chemotherapy.
[24] Ronan Boulmé,et al. Comparison of ultra-deep versus Sanger sequencing detection of minority mutations on the HIV-1 drug resistance interpretations after virological failure , 2014, AIDS (London).
[25] Sarah B. Laskey,et al. Replication-Competent Noninduced Proviruses in the Latent Reservoir Increase Barrier to HIV-1 Cure , 2013, Cell.
[26] C. Delaugerre,et al. Comparison of resistance mutation patterns in historical plasma HIV RNA genotypes with those in current proviral HIV DNA genotypes among extensively treated patients with suppressed replication , 2012, HIV medicine.
[27] R. Kagan,et al. A Genotypic Test for HIV-1 Tropism Combining Sanger Sequencing with Ultradeep Sequencing Predicts Virologic Response in Treatment-Experienced Patients , 2012, PloS one.
[28] M. Hughes,et al. Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine , 2011, Proceedings of the National Academy of Sciences.
[29] K. Metzner,et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. , 2011, JAMA.
[30] V. Calvez,et al. Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia. , 2011, The Journal of antimicrobial chemotherapy.
[31] L. Cuzin,et al. A large French prospective cohort of HIV‐infected patients: the Nadis Cohort , 2009, HIV medicine.
[32] Geneviève Boucher,et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation , 2009, Nature Medicine.
[33] Avettand‐Fènoël Véronique,et al. LTR real‐time PCR for HIV‐1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in HAART area (ANRS CO 01) , 2009 .
[34] J. Mellors,et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy , 2008, Proceedings of the National Academy of Sciences.
[35] Yassine Taoufik,et al. The lymphocyte HIV reservoir in patients on long-term HAART is a memory of virus evolution , 2004, AIDS.
[36] C. Verhofstede,et al. Drug-Resistant Variants That Evolve During Nonsuppressive Therapy Persist in HIV-1–Infected Peripheral Blood Mononuclear Cells After Long-Term Highly Active Antiretroviral Therapy , 2004, Journal of acquired immune deficiency syndromes.
[37] M. Wainberg,et al. Multiple Effects of the M184V Resistance Mutation in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 , 2003, Clinical Diagnostic Laboratory Immunology.
[38] R. Siliciano,et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells , 2003, Nature Medicine.
[39] M. Mouroux,et al. Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure. , 2001, AIDS.
[40] C. Sabin,et al. Reduction in human immunodeficiency virus type 1 mutations associated with drug resistance after initiating new therapeutic regimens in pretreated patients. , 2000, The Journal of infectious diseases.
[41] J. Sninsky,et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). , 1995, The Journal of infectious diseases.